Outpatient Anal Cancer Screening in the Era of COVID-19

Joel Palefsky, MD, FRCP(C)
Professor of Medicine
University of California, San Francisco



CME VIDEOTop of page

About the Presenter:Top of page

Dr. Palefsky completed his MD and residency in Internal Medicine at McGill University and his fellowship in Infectious Diseases at Stanford University. He then joined the faculty at the University of California, San Francisco, where he remains to this day. An international expert on the molecular biology, treatment, pathogenesis, and natural history of anogenital HPV infections, particularly in the setting of HIV, he is the director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center.

Learning Objectives: Top of page

At the completion of this educational session, learners will:

  • Describe the epidemiology of anal HPV infection, high-grade squamous intraepithelial lesions (HSIL) and cancer among people living with HIV (PLWH)
  • Describe the progress of the ANCHOR Study
  • Describe recent advances in screening for anal cancer and HSIL
  • Describe the impact of screening for and treating HSIL in the setting of the COVID pandemic

CME Information:Top of page


This CME activity has approved for AMA PRA Category 1 Credit™ for September 9, 2020 as a live activity.  This activity will also be available as an enduring activity from September 10, 2020, through September 9,2022.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity. - Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose. - Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose. - Dr. Joel M. Palefsky (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Research Grant from Merck; Consultant/Stock Shareholder to Vir Biotechnologies, and Vaccitech; Stock Shareholder in Virion Technologies. Dr. Palefsky will support his presentation and clinical recommendations with the best available evidence from the medical literature and will submit his slides in advance for adequate peer review.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from: Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Evaluation

You must be logged in to post a comment. Login | Register